Neogene Therapeutics
Cell therapy company developing personalized neoantigen-targeting T cell receptor (TCR) therapies for solid tumors. Acquired by AstraZeneca in 2022 for up to $320 million.
Website
https://www.neogene.comLocation
Los Angeles, California, USA & Amsterdam, Netherlands
Founded
2019
Investors
1
Categories
biotech, cell-therapy, oncology, tcr-therapy, personalized-medicine
Notes
Neogene Therapeutics was a clinical-stage cell therapy company focused on developing personalized T cell receptor (TCR) therapies targeting neoantigens in solid tumors. The company's approach involved identifying tumor-specific neoantigens in each patient's cancer and engineering their T cells to recognize and attack these targets.
The company was acquired by AstraZeneca in 2022 for up to $320 million, bringing its neoantigen-targeting TCR platform into AstraZeneca's oncology pipeline to advance cell therapy approaches for solid tumors.
Team
- Carsten Reinhardt, M.D., Ph.D. - Former Chief Executive Officer
- Company now part of AstraZeneca
Additional Research Findings
- Founded in 2019
- Dual headquarters in Los Angeles, California and Amsterdam, Netherlands
- Former portfolio company of Polaris Partners
- Acquired by AstraZeneca in 2022 for up to $320 million
- TCR-based cell therapies targeting neoantigens
- Focus on solid tumor treatment
- Personalized cancer immunotherapy approach
- Now integrated into AstraZeneca's oncology R&D
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Polaris Partners | US | biotech-focused | - | 33 |